Early complications of endobronchial lung volume reduction treatment with endobronchial valves
Journal Title: Gulhane Medical Journal - Year 2020, Vol 62, Issue 2
Abstract
Aims: Endobronchial valve (EBV) treatment is one of the main minimally invasive treatment options for emphysema management. In this study, we aimed to evaluate the early term complication rates of patients having severe emphysema and being treated with EBV. Methods: A total of fifteen patients treated with EBV for bronchoscopic lung volume reduction between November 2017 and January 2019 were included in the study. Pretreatment demographic data, pulmonary function results and exercise capacities were recorded. All complications encountered during the first 3-month period after the EBV treatment were evaluated. The status of collateral ventilation was assessed with Chartis system. Implanted valves were appropriately chosen according to the bronchial lumens’ diameter. All patients were discharged after a minimum of 72 hours of observation. Results: Fifteen bronchoscopic lung volume reduction treatment sessions were performed for fifteen patients. All of them were male. The mean age of the patients was 66.7±6.3 years and the mean disease duration was 11.1±3.7 years. A mean of 3.46 valves were implanted per patient. Early complications were observed in five patients (33.3%) during the 3-month follow-up period after the EBV treatment. Of them, three had chronic obstructive pulmonary disease exacerbation, one had pneumothorax, and the last one had pneumonia. Only one patient died due to the early complications of the valve treatment. Conclusions: Although the number of patients is small, our study demonstrates that EBV treatment can be safely applied with low complication rates as a bronchoscopic lung volume reduction treatment to the patients that have severe heterogeneous emphysema.
Authors and Affiliations
Deniz Doğan, Cantürk Taşçı
Keywords
Related Articles
- EP ID EP684407
- DOI 10.4274/gulhane.galenos.2020.1082
- Views 160
- Downloads 0
Evaluation of risk factors and causative pathogens in bloodstream infections in cancer patients
Aims: Bloodstream infection in cancer patients may cause delays in chemotherapy, prolonged hospital stay, difficulties in diagnosis and treatment, inappropriate treatment, high mortality rates and increased health care c...
Absolute lymphocyte count is a predictor of outcome after splenectomy for immune thrombocytopenia
Aims: Splenectomy is still the standard salvage therapy in immune thrombocytopenia (ITP) cases refractory to corticosteroid therapy. The aim of this study was to evaluate adult ITP patients who underwent splenectomy and...
Erratum-
No summary
Complementary and alternative medicine usage in patients with Familial Mediterranean Fever
Aims: Colchicine is mainstay in the treatment of Familial Mediterranean Fever (FMF). In chronic diseases, complementary and alternative medicine (CAM) methods can be chosen as a non-mainstream treatment. We aimed to iden...
Immunohistochemistry expression of EMA, CD10, CEA, and Bcl-2 in distinguishing cutaneous basal cell from squamous cell carcinoma: A systematic review
Cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most popular neoplastic entities in cutaneous medicine. These two neoplasms are commonly well recognized on the basis of their clinical and h...